Drug Profile
MLN 977
Alternative Names: CMI 977; LDP 977Latest Information Update: 23 Jul 2002
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals
- Class Antiasthmatics
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 23 Jul 2002 Millennium may develop an inhaled formulation of MLN 977
- 23 Jul 2002 Millennium is seeking a development partner with experience in inhalation technology
- 19 Jul 2002 Discontinued - Phase-II for Asthma in USA (PO)